Published guidance, NICE advice and quality standards | Guidance

Showing 491 to 500 of 875

Sort by

Published guidance, NICE advice and quality standards
Title	Reference number	Published	Last updated
Neratinib for extended adjuvant treatment of hormone receptor-positive, HER2-positive early stage breast cancer after adjuvant trastuzumab	TA612	20 November 2019	20 November 2019
Pentosan polysulfate sodium for treating bladder pain syndrome	TA610	13 November 2019	13 November 2019
Ibrutinib with rituximab for treating Waldenstrom's macroglobulinaemia (terminated appraisal)	TA608	30 October 2019	30 October 2019
Ramucirumab for treating unresectable hepatocellular carcinoma after sorafenib (terminated appraisal)	TA609	30 October 2019	30 October 2019
Rivaroxaban for preventing atherothrombotic events in people with coronary or peripheral artery disease	TA607	17 October 2019	17 October 2019
Lanadelumab for preventing recurrent attacks of hereditary angioedema	TA606	16 October 2019	16 October 2019
Xeomin (botulinum neurotoxin type A) for treating chronic sialorrhoea	TA605	9 October 2019	9 October 2019
Idelalisib for treating refractory follicular lymphoma	TA604	2 October 2019	2 October 2019
Pomalidomide with bortezomib and dexamethasone for treating relapsed or refractory multiple myeloma (terminated appraisal)	TA602	25 September 2019	25 September 2019
Lenalidomide with bortezomib and dexamethasone for untreated multiple myeloma (terminated appraisal)	TA603	25 September 2019	25 September 2019